AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04412213 — intervention group
Intervention type: OTHER
Intervention: Stuttering severity instrument for school-age children (SSI-3 Arabic version)
Description: Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
Study NCT03407053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-processed diet
Description: Consuming ultra-processed diet over a 2-week period
Study NCT03407053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unprocessed diet
Description: Consuming unprocessed diet over a 2-week period
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study NCT03835585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gun lock
Description: A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
Study NCT03835585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suicide Risk Assessment
Description: Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
Study NCT03835585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suicide Risk Assessment
Description: Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
Study NCT00660907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glipizide
Description: Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
Study NCT00660907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate
Description: Day 1 q2w: 200 mg/m² IV over 2 hours
Study NCT00660907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride
Description: Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Study NCT02975778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain Monitor™
Description: Pain measured by Pain Monitor™
Study NCT04053075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine cluster detection
Description: Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
Study NCT04053075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced cluster detection
Description: Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Day 1 q2w: 200 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin during radiotherapy
Description: Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours
Study NCT04375605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil during radiotherapy
Description: day 1 - 33: 225 mg/m²/day IV continuously
Study NCT01410409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g x 4/day
Study NCT03147612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given via central catheter
Study NCT03147612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01635816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE Vaccine existing facility
Description: Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
Study NCT03147612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally or IV
Study NCT03147612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT03147612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally or IV
Study NCT03147612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT03147612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT03147612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03147612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT01635816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 1
Description: Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
Study NCT01635816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 2
Description: Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
Study NCT01635816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE vaccine new plant lot 3
Description: Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
Study NCT00423371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
Study NCT00423371 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
Study NCT03835585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning
Description: A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
Study NCT03835585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning
Description: A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
Study NCT03835585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling
Description: A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
Study NCT03835585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lethal Means Counseling
Description: A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
Study NCT01410409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks
Study NCT04235270 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FDC of Macitentan and Tadalafil
Description: Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
Study NCT04235270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10 mg tablet will be administered orally as free combination.
Study NCT04235270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 40 mg tablet will be administered orally as free combination.
Study NCT01781403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
Study NCT01349803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI administered as two puffs BID for 14 days
Study NCT01349803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 14 days
Study NCT01349803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 MDI
Description: PT003 MDI administered as two puffs BID for 14 days
Study NCT01349803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
Study NCT03921554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
Study NCT00398892 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipoic acid
Description: Lipoic acid capsules
Study NCT03206853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Operating Techniques
Description: It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
Study NCT03206853 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hybrid Operating Techniques
Description: It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
Study NCT04058145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
Study NCT04058145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor.
Study NCT02302781 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Several validated questionnaires, depending on moment in fertility work up or treatment.
Study NCT04298554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD Oil
Description: CBD PURE CBD OIL 20mg/1ml concentration
Study NCT04298554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hemp Oil
Description: CBD PURE HEMP OIL
Study NCT04635215 — intervention group
Intervention type: DEVICE
Intervention: Sensura Mio Bodyfit technology ostomy pouches
Description: The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
Study NCT02118389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna
Description: Glucerna 52g meal replacement
Study NCT04430543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%).
Study NCT04430543 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)
Study NCT01410409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazol
Description: 20mg x 1/day for three weeks
Study NCT03378362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial denervation of the wrist joint
Description: Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
Study NCT01410409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
Study NCT01149824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salvinorin A
Study NCT01149824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT01493570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study NCT01410409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.
Study NCT01493570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT00925912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal block
Description: 0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
Study NCT01410409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR
Description: Surgical treatment with insertion of total knee replacement following standard procedures.
Study NCT01410409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.
Study NCT01809457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational poster
Description: educational poster for dental trauma
Study NCT03940339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital myofascial release
Description: The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
Study NCT03940339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
Study NCT04243200 — intervention group
Intervention type: OTHER
Intervention: Hypos can strike twice
Description: The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover.
Study NCT03418922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Specified doses will be administered orally on specified days.
Study NCT03418922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses will be administered intravenously on specified days.
Study NCT03438409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Description: Robotic gait training
Study NCT01026805 — intervention group
Intervention type: DEVICE
Intervention: Interlace Medical 1st Generation Hysteroscopic Morcellator
Description: The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
Study NCT03387540 — intervention group
Intervention type: DRUG
Intervention: ICI
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
Study NCT02797132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA